nimodipine has been researched along with Cognitive Decline in 11 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A total of 126 Chinese patients with post-cerebral infarction MCI recruited from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine between April 2013 and June 2014 were randomized at 1:1: 1 ratio into nimodipine alone (30 mg/time and 3 times daily), acupuncture alone (30 min/time, 6 times/week), and nimodipine + acupuncture groups." | 9.22 | Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial. ( Gan, L; Liu, T; Wang, S; Yang, H; Zhang, B; Zhang, J; Zheng, J, 2016) |
| "Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT, as well as the up-regulation of miR-27a." | 5.56 | Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis. ( Hao, XD; Ji, HM; Li, JW; Li, LR; Ren, JR; Ren, SH; Zhen, ZG, 2020) |
| "CONIVaD (choline alphoscerate and nimodipine in vascular dementia) is a pilot, single-center, double-blinded, randomized trial aimed to assess whether the association of choline alphoscerate and nimodipine is more effective than nimodipine alone in reducing cognitive decline in patients with SVD and mild-to-moderate cognitive impairment." | 5.34 | Association of nimodipine and choline alphoscerate in the treatment of cognitive impairment in patients with cerebral small vessel disease: study protocol for a randomized placebo-controlled trial-the CONIVaD trial. ( Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2020) |
| "A total of 126 Chinese patients with post-cerebral infarction MCI recruited from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine between April 2013 and June 2014 were randomized at 1:1: 1 ratio into nimodipine alone (30 mg/time and 3 times daily), acupuncture alone (30 min/time, 6 times/week), and nimodipine + acupuncture groups." | 5.22 | Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial. ( Gan, L; Liu, T; Wang, S; Yang, H; Zhang, B; Zhang, J; Zheng, J, 2016) |
| "Nimodipine exhibited potentially beneficial effects by ameliorating cognitive decline following scopolamine administration in the hippocampus and prefrontal cortex." | 4.31 | The effect of the calcium channel blocker nimodipine on hippocampal BDNF/Ach levels in rats with experimental cognitive impairment. ( Kaya, AK; Ozturk, A; Saral, O; Saral, S; Topcu, A, 2023) |
| " Fourteen patients (22%) dropped out for reasons including consent withdrawal (n = 9), adverse reactions (n = 4), and stroke (n = 1)." | 3.01 | Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial. ( Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2021) |
| "Nimodipine is a highly prescribed drug for the treatment of cognitive impairment and dementia in Argentina." | 2.94 | Effect of a Social Norm Email Feedback Program on the Unnecessary Prescription of Nimodipine in Ambulatory Care of Older Adults: A Randomized Clinical Trial. ( Ajzenman, N; Bustin, J; Lopez Boo, F; Mastai, R; Tomio, A; Torrente, F; Triskier, F, 2020) |
| " CG combined with NM is better than NM alone." | 1.62 | Cerebralcare Granule® combined with nimodipine improves cognitive impairment in bilateral carotid artery occlusion rats by reducing lipocalin-2. ( Gao, WY; Han, XY; Ji, HX; Jing, SS; Li, X; Liu, CX; Man, SL; Qiao, O; Wang, J; Wang, WZ; Zhang, XY; Zhang, Y, 2021) |
| "Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT, as well as the up-regulation of miR-27a." | 1.56 | Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis. ( Hao, XD; Ji, HM; Li, JW; Li, LR; Ren, JR; Ren, SH; Zhen, ZG, 2020) |
| " In the observation group, patients were given rosuvastatin in combination with nimodipine, and other patients were given nimodipine in the control group." | 1.51 | Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. ( Liu, N; Yang, C; Zhang, J, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 6 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, XY | 1 |
| Jing, SS | 1 |
| Qiao, O | 1 |
| Han, XY | 1 |
| Wang, WZ | 1 |
| Ji, HX | 1 |
| Zhang, Y | 1 |
| Li, X | 1 |
| Wang, J | 1 |
| Man, SL | 1 |
| Liu, CX | 1 |
| Gao, WY | 1 |
| Topcu, A | 1 |
| Saral, S | 1 |
| Ozturk, A | 1 |
| Saral, O | 1 |
| Kaya, AK | 1 |
| Li, JW | 1 |
| Ren, SH | 1 |
| Ren, JR | 1 |
| Zhen, ZG | 1 |
| Li, LR | 1 |
| Hao, XD | 1 |
| Ji, HM | 1 |
| Torrente, F | 1 |
| Bustin, J | 1 |
| Triskier, F | 1 |
| Ajzenman, N | 1 |
| Tomio, A | 1 |
| Mastai, R | 1 |
| Lopez Boo, F | 1 |
| Salvadori, E | 2 |
| Poggesi, A | 2 |
| Donnini, I | 2 |
| Rinnoci, V | 2 |
| Chiti, G | 2 |
| Squitieri, M | 2 |
| Tudisco, L | 2 |
| Fierini, F | 2 |
| Melone, A | 2 |
| Pescini, F | 2 |
| Pantoni, L | 2 |
| Hu, M | 1 |
| Liu, Z | 1 |
| Lv, P | 1 |
| Wang, H | 1 |
| Zhu, Y | 1 |
| Qi, Q | 1 |
| Xu, J | 1 |
| Gao, L | 1 |
| Zhang, J | 2 |
| Liu, N | 1 |
| Yang, C | 1 |
| Qin, Y | 1 |
| Li, G | 1 |
| Sun, Z | 1 |
| Xu, X | 1 |
| Gu, J | 1 |
| Gao, F | 1 |
| Wang, S | 1 |
| Yang, H | 1 |
| Zhang, B | 1 |
| Liu, T | 1 |
| Gan, L | 1 |
| Zheng, J | 1 |
| Moran, JM | 1 |
| Pedrera-Zamorano, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment[NCT03228498] | Phase 2 | 62 participants (Actual) | Interventional | 2017-05-02 | Completed | ||
| Combining Acupuncture and Acupressure for Community-dwelling Elderly With Dementia: an Assessor-blinded, Randomized Controlled Trial[NCT04305951] | 248 participants (Anticipated) | Interventional | 2021-10-05 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for nimodipine and Cognitive Decline
7 other studies available for nimodipine and Cognitive Decline
| Article | Year |
|---|---|
Cerebralcare Granule® combined with nimodipine improves cognitive impairment in bilateral carotid artery occlusion rats by reducing lipocalin-2.
Topics: Animals; Carotid Arteries; China; Cognitive Dysfunction; Dementia, Vascular; Disease Models, Animal; | 2021 |
The effect of the calcium channel blocker nimodipine on hippocampal BDNF/Ach levels in rats with experimental cognitive impairment.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Brain-Derived Neurotrophic Factor; Calcium Channel Blo | 2023 |
Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis.
Topics: Animals; Antihypertensive Agents; Cognitive Dysfunction; Disease Models, Animal; Down-Regulation; Ma | 2020 |
Nimodipine activates neuroprotective signaling events and inactivates autophages in the VCID rat hippocampus.
Topics: Animals; Autophagy; Carotid Artery Diseases; Carotid Artery, Common; Cognitive Dysfunction; Cyclic A | 2017 |
Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease.
Topics: Activities of Daily Living; Aged; C-Reactive Protein; Cerebral Small Vessel Diseases; Cholesterol; C | 2019 |
Comparison of the effects of nimodipine and deferoxamine on brain injury in rat with subarachnoid hemorrhage.
Topics: Animals; Atrophy; Cognitive Dysfunction; Deferoxamine; Disease Models, Animal; Ferritins; Male; Maze | 2019 |
Comments on "Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial".
Topics: Acupuncture Therapy; Cerebral Infarction; Cognitive Dysfunction; Humans; Nimodipine; Safety; Treatme | 2017 |